anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

163,681-163,740 of 319,975

filter-aware
19
TTM stands for Trailing Twelve Months. The table provides a breakdown of cash flow adjustments.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Appendix1 hit
01
Slide 1
The infinity symbol is used as a framing device for the imagery.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
02
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
03
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
04
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
05
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
06
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
07
The slide uses an infinity loop to symbolize the continuous cycle between patient and science.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
08
The slide uses a 2x3 grid layout to present five key strategic pillars.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
09
The slide uses a hub-and-spoke visual metaphor to show the drug's broad applicability across multiple disease states.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
10
The slide uses a process-like flow to connect disease states to specific clinical data and future opportunities.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
11
The slide uses a comparison matrix structure to justify the expansion of a clinical franchise into a new indication.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
12
The diagram is a variation of a flywheel or infinity loop process.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
13
The slide uses a biological neuron metaphor to illustrate a business platform strategy.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
14
The slide uses a Venn-like diagram to connect core company values to specific market and pipeline achievements.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
15
The slide uses a Venn-like diagram to connect three core pillars to six specific business achievements.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
16
The slide features a stylized circular cutout showing a smiling woman, set against a background of molecular structures.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
17
The slide uses a numbered list to explain a biological process (pinocytosis, binding, rescue, release) mapped to a visual diagram.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
18
The slide uses a numbered process/comparison flow to contrast binding modes.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
19
The chart shows that Efgartigimod maintains FcRn volume similar to 'No treatment', whereas the 'Control anti-FcRn mAb' causes a significant reduction in volume over time.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
20
The slide uses a causal flow diagram to explain the mechanism of action.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
21
Data from Phase 3 ADAPT trial; includes comparison to Phase 2 pemphigus trial findings.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
22
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
23
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
24
The slide uses a structured layout to define the disease state and market opportunity.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
25
The diagram uses a bubble-cluster visualization to show the relationship between different autoantibodies and clinical conditions.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
26
The slide uses a circular process flow to explain the pathology of Immune-Mediated Necrotizing Myopathy (IMNM).argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
27
The slide uses a process-flow framework to show how autoantibodies trigger specific biological pathways (myolysis, capillary disruption, interferon production) leading to muscle atrophy.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
28
The diagram illustrates a hub-and-spoke model where the autoantibody is the central mediator.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
29
The slide illustrates the diversity of autoantibodies in myositis patients, supporting the thesis that a broad-acting therapy like Efgartigimod is effective.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
30
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
31
The slide shows 8 individual patient longitudinal plots. Each plot has dual y-axes (CK and Anti-SRP54) and a shared x-axis (Days).argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
32
The chart is a Kaplan-Meier survival curve showing 'DOI-free Survival Probability' over time in weeks.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
33
ProDERM study data comparing IVIg and placebo efficacy over time.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
34
Includes two dot plots showing grip/muscle strength and two microscopy images showing necrosis and complement deposition.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
35
The chart uses a diagonal line to represent growth or accumulation of patient segments.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
36
The slide outlines a clinical trial protocol involving 180 patients, stratified by condition and severity, with a 26-week duration and specific primary/secondary endpoints.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
37
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
38
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
39
The slide uses a structured 4-column layout to summarize the disease profile.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
40
The slide depicts a step-by-step biological pathway (1-6) showing how autoantibodies lead to blister formation. It also highlights the therapeutic target Efgartigimod.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
41
The slide uses a before-after structure to contrast WT mice (susceptible) with FcRn-/- mice (resistant) and shows the impact of HDIG treatment.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
42
The funnel structure implies a progression toward higher selectivity and better outcomes.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
43
The slide presents three distinct clinical datasets (IVIg, Protein A Immunoadsorption, and PLEX) to support the thesis that IgG-targeted therapies lead to fast remissions.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
44
Uses a horizontal progression arrow to show the transition from initial indication to adjacent indications.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
45
Clinical trial design diagram showing a 1:1 randomization between Efgartigimod and Placebo over 36 weeks.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations 1 hit
46
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
47
Branded Argenx presentation slide.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
48
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
49
Includes names of presenters and company logo.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
50
The diagram shows the classical, lectin, and alternative pathways converging at C3 convertase, with C2 highlighted as a target.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
51
The slide uses a process flow diagram to illustrate the complement system and justifies targeting C2 over other components.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
52
The slide uses a process flow diagram to explain the mechanism of action for a potential therapeutic intervention.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a biological pathway diagram to justify a therapeutic target.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
54
The slide uses a process flow diagram to justify targeting C2. It contrasts this with other potential targets (labeled 1 and 2) and highlights the benefits of C2 inhibition.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
55
The slide uses a circular process diagram to explain the biological mechanism of the drug.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a timeline-like structure to show dose escalation cohorts for IV and SC administration.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
57
The slide presents clinical trial safety data for ARGX-117, highlighting that most adverse events are low grade and unrelated to the drug.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
58
SAD = Single Ascending Dose. PD = Pharmacodynamic.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
59
The slide shows two line charts comparing different dosing regimens over time.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit